ANZCTR search results

This is a randomised wait-list control study. Participants will be randomised to participate in either a structured, individualised, supervised exercise program (intervention group) or to usual care (wait-list control group). Participants allocated to the intervention group will complete a 12 week, 3 times per week, structured, individualised, 1 on 1 supervised exercise program (mixed between face to face and "live" telehealth on Microsoft teams). Participants allocated to the control group will continue with their usual care over the 12 week period and then be invited to receive the full 12 weeks intervention on completion of the 36 weeks follow up assessment period. Blinded assessments will be undertaken at baseline (week 0), following the intervention (Week 12), and at follow-up (36 weeks).

This study aims to evaluate the ecofit program (which comprises an app and web-based resources) across remote and rural primary health care settings in the Hunter New England Health District for patients with T2D within the Diabetes Alliance Project Plus study. The current study will assess the reach, adoption, appropriateness, feasibility, fidelity and reach of the ecofit program among general practitioners and general practice staff. The study will also assess the reach, acceptability dosage and effectiveness of the ecofit program among DAP+ patients, It is hypothesized that the effective implementation of the ecofit program within DAP+ as a physical activity resource for adults with T2D will result in DAP+ patients participating in increased physical activity and experiencing the associated health benefits.

Low-calorie sweeteners (LCS) have been widely used in food and beverages in recent decades. However, a recent World Health Organisation (WHO) report highlighted that people who consume LCS regularly have an increased risk of developing type 2 diabetes (T2D). Acesulfame potassium (Ace-K) is a widely used low-calorie sweetener that is absorbed from the gut and excreted in the urine. We want to find out whether Ace-K consumption reduces the amount of glucose excreted in the urine in healthy humans.

The purpose of this study is to implement and evaluate The Enhancing Women’s Recovery after Cancer Treatment Program (known as RECENTRE) as standard practice after treatment, Queensland-wide, across Mater Misercordiae facilities. RECENTRE is a digitally enabled lifestyle program for prevention of additional chronic disease in women treated for breast and gynaecological cancer. Who is it for? You may be eligible for this study if you are a female who has been diagnosed with breast or gynaecological cancer, that has completed intensive cancer treatment more than 4 weeks ago. Study details In this study, all participants receive the 12-week RECENTRE intervention targeting physical activity, diet, alcohol management, body weight, smoking cessation, sleep, stress, menopausal symptoms, and sexual health. These strategies are personalised based on individual goals and functional capacities. The RECENTRE program involves online modules and virtual consultations, if required. Participants will be followed up for 6 months, and asked to complete questionnaires throughout the study to follow-up on overall health. It is hoped that this study will help determine if the RECENTRE program is an effective and safe way to provide support to women after cancer treatment.

This observational study aims to assess whether a residual heparin effect is contributing to post-operative bleeding in cardiac surgical patients at a single institution. It will also assess whether testing for a residual heparin effect will help in reduce the transfusion of blood components perioperatively. The hypothesis being tested is that a proportion of patients undergoing cardiac surgery are returning to ICU with heparin activity affecting their normal coagulation and that this might result in inappropriate administration of platelets and other blood components.

This is a feasibility and acceptability study investigating the use of a transitional care intervention for frail older adults discharging from hospital and returning home. All participants recruited will be given the intervention. Primary outcomes look at feasibility and acceptability of the intervention. Comparison of secondary outcome measures will be conducted for quality of life and anxiety and depression scores at baseline and 1-month. With further follow up of readmissions, institutionalisation and mortality at 1-month, 3-months, 6-months, and 12-months. This project proposes that setting 3 patient-centred priorities with telehealth follow up on these priorities is found to be a feasible and acceptable transitional care intervention for frail older adults within Blacktown and Mount Druitt Hospitals.

This study will compare walk-and-talk therapy to conventional indoor therapy for helping men with low mood. While conventional indoor therapy is effective, some men may find it challenging to engage in. Walk-and-talk therapy offers an alternative and more informal setting, which may make it easier for some men to open up and benefit from therapy. By comparing these two approaches, the study aims to discover which one works better for improving mood in men. We expect that participation in either arm will be beneficial for men, but hypothesise that men in the walk-and-talk condition will report greater reductions in overall psychological distress at the conclusion of therapy. Ultimately, the findings could lead to more personalised and effective treatment options for men experiencing low mood.

This study will use electronic medical records from the Austin Health database to evaluate the outcomes and complications in patients undergoing major abdominal surgery. These results may be used to aid prognostication of post-operative major abdominal surgery patients, as well as identify, and therefore modify, factors that may predispose patients to poorer post-operative outcomes and ultimately reduce overall morbidity and mortality in this patient cohort.

This pilot study is evaluating the feasibility of providing an oral prebiotic fibre supplement during treatment for acute leukemia. It will assess tolerance and whether prebiotic supplementation can improve the microbiome and reduce complications. Patients may be eligible to join this study if they are aged 18 years and older undergoing treatment for acute leukemia at the Royal Brisbane and Women’s Hospital (RBWH). Participants in this study will be randomly allocated to the intervention group or the control group. Participants allocated to the intervention will receive an oral prebiotic fibre supplement from the start of induction treatment until the end of their consolidation treatment. The control group will receive usual care. It is hoped that prebiotic supplementation will support the microbiome and improve health outcomes for participants undergoing acute leukemia treatment.

Residential aged care facilities are at higher risk of COVID-19 and airborne pathogen (influenza, RSV) outbreaks and their consequences. Upper room GUV (UR-GUV) light has the potential to substantially reduce the transmission of airborne pathogens, including viruses, by inactivating them when in contact with the ultraviolet C (UV-C) light emitted from the device. The advantages of UR-GUV are that it can potentially deliver high levels of effective air changes (or clean air), such that transmission may be interrupted; and that it does not rely on interventions requiring behavioural uptake or modification. This study aims to determine if in RACFs in metropolitan Melbourne and Greater Geelong, Victoria, Australia, the installation of UR-GUV in common rooms reduces the event (“incidence”) rate of COVID-19 among residents, compared to standard practices alone over 12 months. This is an open-label cluster randomised controlled trial (cRCT) conducted in real-world setting, using routine systems for infection control and prevention. The study plans to recruit up to 60 residential aged care facilities, mostly from large multi-facility aged care providers. Half (30) of the facilities will be intervention facilities with UR-GUV installed. The other half will be control facilities with no UR-GUV installed but will continue standard of care. The study involves the routine collection of COVID-19, influenza and RSV case data over a 12-month period in these intervention facilities and compare it with cases in the control facilities. The study will also measure the effectiveness of GUV at reducing other respiratory illnesses. These findings will help inform the role of UR-GUV as part of a suite of available interventions to prevent and manage COVID-19, other respiratory illnesses and enhance preparedness for future airborne pathogen threats and pandemics.